Literature DB >> 2448408

Blood coagulation in postmenopausal women given estrogen treatment: comparison of transdermal and oral administration.

N Alkjaersig1, A P Fletcher, D de Ziegler, K A Steingold, D R Meldrum, H L Judd.   

Abstract

The responses of the blood coagulation and related systems were studied in 23 postmenopausal women, all of whom received, in randomized order, therapy with conjugated oral estrogens (0.625 and 1.25 mg daily) and transdermally administered estradiol in doses of 25, 50, 100, and 200 micrograms/24 hr. Neither plasma fibrinopeptide A determinations nor plasma fibrinogen chromatographic findings were altered; thus there is no evidence of accelerated fibrinogen turnover with either form of therapy. However, alpha 1-antitrypsin and plasminogen concentrations were significantly increased with the higher dosage of oral but not with transdermally administered estrogen. Similarly, ceruloplasmin concentration was significantly elevated with both oral doses but was unchanged by transdermal therapy.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2448408

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  5 in total

Review 1.  A risk-benefit appraisal of transdermal estradiol therapy.

Authors:  A Cheang; R Sitruk-Ware; W H Utian
Journal:  Drug Saf       Date:  1993-11       Impact factor: 5.606

Review 2.  Transdermal estradiol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of menopausal complaints.

Authors:  J A Balfour; R C Heel
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

3.  Hemostatic Factors and Ischemic Heart Disease Risk Among Postmenopausal Women.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

Review 4.  Transdermal estradiol. A review of its pharmacological profile, and therapeutic potential in the prevention of postmenopausal osteoporosis.

Authors:  J A Balfour; D McTavish
Journal:  Drugs Aging       Date:  1992 Nov-Dec       Impact factor: 3.923

5.  Is the WHI relevant to HRT started in the perimenopause?

Authors:  S Mitchell Harman; Eliot A Brinton; Thomas Clarkson; Christopher B Heward; Harvey S Hecht; Richard H Karas; Debra R Judelson; Frederick Naftolin
Journal:  Endocrine       Date:  2004-08       Impact factor: 3.925

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.